Eli Lilly
Top Five Articles on GenomeWeb Last Week: Illumina, BillionToOne, Foundation Medicine, Qiagen, More
Last week, GenomeWeb's readers were most interested in news about Illumina pricing a $500 million public notes offering.
FDA Approves Illumina Cancer Genomic Profiling Assay as CDx for Kinase Inhibitors From Bayer, Lilly
The test's first CDx approvals are for Bayer's Vitrakvi in solid tumors and for Lilly's Retevmo in non-small cell lung cancer.
Chugai Gains Japanese Approval for CDx for Eli Lilly's Retevmo
Roche's FoundationOne CDx cancer genomic profiling test was approved for the RET receptor tyrosine kinase inhibitor for RET fusion-positive solid tumors.
FDA Approves FoundationOne CDx for Eli Lilly's Retevmo
The tissue-based test can determine if Retevmo is an appropriate treatment for patients with RET gene fusions.
Biocartis, Eli Lilly Partner for Spanish NSCLC Biomarker Study
The study aims to establish how Biocartis' Idylla molecular testing platform can eventually be used to improve community-based diagnostic workflows in the US.
Jun 18, 2020